DBV Technologies (NASDAQ:DBVT) Sets New 52-Week Low – What’s Next?

by · The Markets Daily

DBV Technologies S.A. (NASDAQ:DBVT – Get Free Report)’s share price hit a new 52-week low during mid-day trading on Wednesday. The company traded as low as $8.90 and last traded at $9.03, with a volume of 344,103 shares changing hands. The stock had previously closed at $9.55.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the company. HC Wainwright reissued a “buy” rating on shares of DBV Technologies in a research note on Tuesday, June 30th. Cantor Fitzgerald restated an “overweight” rating on shares of DBV Technologies in a report on Thursday, September 10th. Citizens Jmp raised their price objective on DBV Technologies from $47.00 to $55.00 and gave the company a “market outperform” rating in a research note on Tuesday, June 30th. Citigroup reaffirmed a “market outperform” rating on shares of DBV Technologies in a research note on Wednesday, September 30th. Finally, Wall Street Zen cut DBV Technologies from a “hold” rating to a “sell” rating in a report on Saturday, July 4th. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $48.50.

Get Our Latest Report on DBV Technologies

DBV Technologies Stock Down 5.4%

The stock’s fifty day simple moving average is $12.70 and its 200-day simple moving average is $16.01.

Hedge Funds Weigh In On DBV Technologies

A number of institutional investors have recently modified their holdings of DBVT. Vivo Capital LLC grew its position in shares of DBV Technologies by 8.4% in the first quarter. Vivo Capital LLC now owns 2,667,569 shares of the company’s stock valued at $55,726,000 after purchasing an additional 205,943 shares during the period. ADAR1 Capital Management LLC acquired a new position in DBV Technologies in the first quarter valued at $21,159,000. Perceptive Advisors LLC purchased a new position in DBV Technologies during the first quarter worth about $20,146,000. Atika Capital Management LLC lifted its position in DBV Technologies by 31.1% during the first quarter. Atika Capital Management LLC now owns 271,300 shares of the company’s stock worth $5,667,000 after buying an additional 64,419 shares during the period. Finally, Elmind Capital LP purchased a new position in DBV Technologies during the first quarter worth about $5,536,000. Institutional investors and hedge funds own 71.74% of the company’s stock.

DBV Technologies Company Profile

(Get Free Report)

DBV Technologies is a clinical-stage biopharmaceutical company focused on developing treatments for food allergies and other immune-mediated conditions. The company’s technology is designed to deliver therapeutic proteins through the skin without needles, with the goal of gradually modifying the immune system’s response to specific allergens.

DBV Technologies’ principal product candidate is Viaskin Peanut, an investigational epicutaneous immunotherapy designed to expose patients to small amounts of peanut protein through a wearable patch.

Further Reading